Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management.
Bridoux F et al. Kidney Int. 2016 Oct 20. pii: S0085-2538(16)30487-2. doi: 10.1016/j.kint.2016.09.004. [Epub ahead of print].

Polyclonal Localized Light Chain Amyloidosis-A Distinct Entity?
Ravindran A et al. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):588-592. doi: 10.1016/j.clml.2016.08.004.

Prevalence, incidence and survival of smoldering multiple myeloma in the United States.
Ravindran A et al. Blood Cancer J. 2016 Oct 21;6(10):e486. doi: 10.1038/bcj.2016.100.

Primary plasma cell leukemia 2.0: Advances in biology and clinical management.
Neri A et al. Expert Rev Hematol. 2016 Oct 19. [Epub ahead of print].

Temporal and Spatial Correlation Between Choroidal Thickness and Visual Function in a Case of POEMS Syndrome.
González-Martin-Moro J et al. Ocul Immunol Inflamm. 2016 Oct 11:1-4. [Epub ahead of print].

Establishment of an innovative staging system for extramedullary plasmacytoma.
Zhu Q et al. BMC Cancer. 2016 Oct 8;16(1):777.

Systemic Amyloidosis Masquerading as Intractable Cardiomyopathy.
Cilia L et al. R I Med J (2013). 2016 Oct 4;99(10):54-56.

Nail Changes of Systemic Amyloidosis After Bone-Marrow Transplantation in a Patient With Multiple Myeloma.
Oberlin KE et al. JAMA Dermatol. 2016 Sep 28. doi: 10.1001/jamadermatol.2016.3178. [Epub ahead of print].

Localized axillary milia en plaque: a rare cutaneous case presentation of systemic amyloidosis.
Dickison P et al. Clin Exp Dermatol. 2016 Oct;41(7):764-7. doi: 10.1111/ced.12914.